- Previous Close
0.0000 - Open
0.0150 - Bid 0.0008 x --
- Ask 1.0000 x --
- Day's Range
0.0150 - 0.0150 - 52 Week Range
0.0150 - 0.0300 - Volume
457,525 - Avg. Volume
3,879 - Market Cap (intraday)
78.32M - Beta (5Y Monthly) 1.15
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date Feb 23, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials, that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
actinogen.com.auRecent News: ATGGF
View More
Performance Overview: ATGGF
Trailing total returns as of 3/17/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATGGF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATGGF
View MoreValuation Measures
Market Cap
59.08M
Enterprise Value
44.89M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.16
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-107.03%
Return on Assets (ttm)
-31.46%
Return on Equity (ttm)
-53.73%
Revenue (ttm)
9.02M
Net Income Avi to Common (ttm)
-9.66M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
22.87M
Total Debt/Equity (mrq)
1.21%
Levered Free Cash Flow (ttm)
-5.31M
Company Insights: ATGGF
ATGGF does not have Company Insights